Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (451-460 of 636) with videos related to

Pageof 64
Sort By:
The New England Journal of Medicine|September 1, 2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromesLars Wallentin, Richard C Becker, Andrzej Budaj, et al.
Circulation|February 21, 2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.
American Heart Journal|December 9, 2019
Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillationSean D Pokorney, DaJuanicia N Holmes, Peter Shrader, et al.
American Heart Journal|January 2, 2022
Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions - proceedings from the CEC Summit 2018Abhinav Sharma, Kenneth W Mahaffey, Charles Michael Gibson, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|September 17, 2018
Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|March 31, 2021
Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II)Larry R Jackson, Peter Schrader, Laine Thomas, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 7, 2021
Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID TrialJemi Galani, Hillary Mulder, Frank W Rockhold, et al.
Journal of the American College of Cardiology|July 19, 2020
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight CommitteeGordon F Tomaselli, Kenneth W Mahaffey, Adam Cuker, et al.
Circulation|November 12, 2023
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and AlbuminuriaBrendon L Neuen, Hiddo J L Heerspink, Priya Vart, et al.
The Lancet. Diabetes & Endocrinology|November 28, 2024
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trialsSunil V Badve, Anika Bilal, Matthew M Y Lee, et al.
Pageof 64

Showing results (451-460 of 636) with videos related to

Sort By:
Pageof 64
The New England Journal of Medicine|September 1, 2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromesLars Wallentin, Richard C Becker, Andrzej Budaj, et al.
Circulation|February 21, 2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.
American Heart Journal|December 9, 2019
Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillationSean D Pokorney, DaJuanicia N Holmes, Peter Shrader, et al.
American Heart Journal|January 2, 2022
Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions - proceedings from the CEC Summit 2018Abhinav Sharma, Kenneth W Mahaffey, Charles Michael Gibson, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|September 17, 2018
Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|March 31, 2021
Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II)Larry R Jackson, Peter Schrader, Laine Thomas, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 7, 2021
Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID TrialJemi Galani, Hillary Mulder, Frank W Rockhold, et al.
Journal of the American College of Cardiology|July 19, 2020
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight CommitteeGordon F Tomaselli, Kenneth W Mahaffey, Adam Cuker, et al.
Circulation|November 12, 2023
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and AlbuminuriaBrendon L Neuen, Hiddo J L Heerspink, Priya Vart, et al.
The Lancet. Diabetes & Endocrinology|November 28, 2024
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trialsSunil V Badve, Anika Bilal, Matthew M Y Lee, et al.
Pageof 64